3D Cell Cultures: Technologies and Global Markets
Report Highlights
The three dimensional cell culture market was $438.1 million in 2013. This market is expected to grow to $586.1 million in 2014 and about $2.2 billion in 2019, with a compound annual growth rate (CAGR) of 30.1%.
Report Includes
- An overview of the global markets and technologies for 3D cell cultures.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Information on 3D technologies with a focus on representative platforms including cube, spherical droplet, stacked plate, magnetic bead, and other platforms.
- Value chain analysis at the following levels: key innovation or founding intellectual property, prototyping, beta testing, and research collaborations or reltationship building.
- Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities.
- Relevant patent analysis including recent activity and a list of key patents.
- Comprehensive profiles of major players in the industry.
Report Scope
The scope of the report encompasses the major types of 3D cell culture that have been used, as well as the major applications being developed by industry, academic researchers and their commercialization offices, and government agencies. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed. Other influential factors such as screening strategies for pharmaceuticals have also been included.
Analyst Credentials
Robert Hunter is a senior management consultant, commercialization consultant and technology and market analyst with over 20 years of experience in life sciences and healthcare. Recent consulting includes market/technology analysis and forecasting of customer adoption and revenue for a high content screening (HCS) technology leader. He is an early investor in a company using stem cells for predictive drug safety testing in vitro. He has a B.S. in Mechanical Engineering from Clemson University and Master of Business Administration from The Tuck School of Business at Dartmouth.
